Zepbound while breastfeeding: what the lactation study did and did not show

Brand-specific education, not a Beema product pitch

Zepbound is Eli Lilly’s FDA-approved tirzepatide product for chronic weight management in eligible adults and for obstructive sleep apnea in adults with obesity. This page summarizes labeled lactation and reproductive language. Beema Health does not offer Zepbound on this marketing site. Do not use this article to justify switching products.

If you are pregnant, the PI says to discontinue Zepbound when pregnancy is recognized. Weight loss is not recommended in pregnancy. Go to obstetric care, not to a restart timeline.

What the lactation study measured

The PI describes subcutaneous administration of a single 5 mg dose to 11 healthy lactating adults. Tirzepatide in milk was undetectable in most samples (limit of detection 4 ng/mL in the description) or low relative to the maternal dose, with last measurable concentrations around five days after the dose in the remaining samples. Cumulative amount in milk was described as small compared with the dose. AUC in milk could not always be calculated.

Missing pieces are explicit: no infant outcomes, no milk-production outcomes, not a multi-dose maintenance study, not a study in medically complex postpartum patients. Treat it as early pharmacology, not as a pediatric safety trial.

The sentence FDA still wants clinicians to use

After presenting the data, the label returns to the standard lactation framework: consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Zepbound and any potential adverse effects on the infant from Zepbound or from the underlying maternal condition.

Your “clinical need” might be obesity-related disease, sleep apnea, or something a clinician has ranked against feeding goals. A marketing page cannot rank those for you. CDC breastfeeding guidance can inform the feeding side of that balance. ACOG postpartum guidance can inform the recovery side. Neither document is a Zepbound authorization.

Maternal side effects that can still affect feeding

Nausea, vomiting, constipation, and diarrhea are common. Dehydration can reduce milk supply and harm kidneys. Severe abdominal pain needs urgent evaluation for pancreatitis or gallbladder disease, which are labeled risks. Those problems do not require the infant to receive tirzepatide in milk in order to matter.

If you cannot eat or drink, that is a maternal emergency pathway, not a cue to push through a titration because you want faster weight change.

If supply drops after a dose increase

A dip in pumped volume after a titration week is more often about maternal intake, fluids, and exhaustion than about a proven tirzepatide effect on milk synthesis, because production data are missing. Still, it is a practical problem. A lactation clinician can look at latch, frequency, and supplementation. The Zepbound prescriber can look at whether GI side effects are driving dehydration.

Do not add unregulated “lactation teas” that contain herbs with their own drug interactions without telling both clinicians. Do not double the infant’s formula and double the tirzepatide dose in the same weekend as a self-experiment.

If the infant is premature, has hypoglycemia, or has other medical needs, the unknown infant-effect box on the label should weigh more heavily toward waiting or toward specialist input. Healthy-term milk-concentration data do not automatically extend to the NICU.

Questions for the prescriber and the baby’s clinician

Ask how the single-dose 5 mg milk data do or do not apply to your dose. Ask whether waiting until after weaning is an option. Ask how to handle oral contraceptives. Ask what symptoms in the infant should trigger a call. Ask whether a pregnancy registry applies if exposure continues or if pregnancy occurs.

Do not stop other postpartum medicines (including thyroid hormone or antidepressants) to “make room” for Zepbound without those prescribers involved.

Frequently asked questions

Sources

1. [1] Zepbound (tirzepatide) prescribing information. Eli Lilly. Section 8.2 Lactation, including the single-dose milk study, and section 8.3 contraception.
2. [2] Zepbound Medication Guide. Eli Lilly. Patient information on pregnancy and feeding.
3. [3] Mounjaro (tirzepatide) prescribing information. Eli Lilly. Lactation section for the diabetes brand of tirzepatide.
4. [4] Centers for Disease Control and Prevention. Breastfeeding recommendations and guidance.
5. [5] American College of Obstetricians and Gynecologists. Optimizing Postpartum Care. Committee Opinion No. 736.